Member Info for Adastra

A lot going on here both within the Company, and by inference, outside it. BioMerieux and Novo are the first movers as the 3yr IPO takeover protection expires on October 5th. I will be amazed if other big pharmas and limited competitors like Illumina and possibly Roche don't start to take an overt interest. The pace and price should really start to gain momentum now with just 2 months to protection expiry.

Oxford Nanopore Technologies set for up to £60M injection from investment giant

Massive vote of confidence as big pharma starts to position before IPO takeover protection runs out on October 5th. That's BioMerieux and Novo now on board......next??

Https://www.facebook.com/share/v/2epskBUGsBTB9LiQ/

Yep. Great time to take advantage of pullbacks. Trajectory towards end of IPO takeover protection on October 5th forming established pattern of strong rise, pullback, then strong rise again towards £2.40 and parity with BioMerieux 7% stake ..... and then some.

DNA is the key to us and everything. Sequencing unlocks the future for humanity. The age of blockbuster drugs is well past and the future is genomic medicine. Targeted. Oxford Nanopore with its peers is on the cusp of a Healthcare resolution. Nvidia provided the shovels for the AI goldrush and Oxford Nano provides the shovels for the BI goldrush. Still not too early to board the train.

BioMerieux is precluded from bidding in the first instance due to restrictions when it purchased the shares at £2.39 last October. That restriction terminates if a bidder comes forward as looks increasingly possible when the 3yr IPO takeover protection ends on October 6th. The CEO has repeatedly warned that predatory interest is definitely there which was why the B and C protection shares were issued. The current MCap is very vulnerable given adequate runway of cash and escalating growth.

Cheap as chips imo at this price. Excellent basic paper business with great coffee cup recycling green driver plus expanding advanced materials division with new divisional manager. Superb opportunity with this oversold pullback. Hold and smile imo.

The AGM provided no reassurance on progress at all. Cash burn is seriously out of control and current management seems incapable of addressing key issues. Yes, it looks a penny stock bargain......but only at face value. I agree with the previous comment that can burn is so high as to probably require additional funding at year end. Barring a complete reshuffle the only way out here is for a competent larger FTSE engineer to end the broken promises imo.

Andy Walton is certainly the right man right time to really stimulate growth in the AM division. The new website highlights the cutting-edge functions and capabilities of the group. It looks slick and polished and acts as a real showcase for projects and offerings. Spot-on. It's so good that with JC trading at below current NAV the group could well appeal to a big player.

Funds and fund managers - waste of time. DYOR.

Ondine is a gamechanger. I invested in Immupharma in Jan/Feb and posted multiple reasons to buy at 1.3p. It has doubled in under a month. Ondine is similarly undervalued It's technology is cutting edge and is now snowballing after years of proof of concept and first-mover adoption.

Reducing antibiotic use is the single biggest driver in global Healthcare as we are unprepared for the next (inevitable) pandemic. Steriwave goes a long way to helping resolve Hospital acquired infections and it's multiple potential applications are being addressed. I can see many major companies being interested in picking up this tiddler before it flies above the radar.

Like yourself, having done lengthy background research I expect this to be a highly rewarding share. The timeframe I set myself is medium to long term rising progressive from around this level. There is always the underlying possibility that newsflow or an opportunistic bid could cause this to rise disproportionately.

Most sensible comment yet. The bigger picture here often gets obscured by negative posters with no shareholding here. Horizon scanning either short or long term here looks positive.

Flash 212.....Victor Meldrew...same negatives here as you post on Aptamer Dekel.......yes, you got out at 1.7p.... have you really nothing better to do?

Apart from the fact that the sale of a block of 11% INC shares could certainly be sold at this time OFF market, the sale is neither necessary nor desirable at present. Newsflow on several fronts is imminent and this is the perfect time imo to grab the baton. DTR and make your own decisions here don't rely on posters like me or Flash or anyone else. All the information you need to make an informed decision is there and, like me, you can contact Immupharma yourself to aid your thought process.

It's all conjecture. The facts are out there with Lupuzor lined up for a funded Ph3 trial and 4 other candidates for potential upfront Royalty deals. We have the never ending concentration however on funding. Cash is tight until newsflow, as promised, is forthcoming but prudent management has many options. Immupharma has over £1 of Incanthera shares which it could capitalise tomorrow IF required. The fact that it has not happened means funds are ok as the CEO has previously assured. Personally, I'd prefer them to keep the INC shares for future dividends but needs must. I just disagree fundamentally with the debate revolving around a non existent issue when so many short term triggers are already set. Patience, positive news will flow soon.

Change the record Wildtiger....your constant negative moan befits the fact you have neither shareholding nor any information here other than conjecture.

Lupuzor is awaiting its Ph3 trials protocols and then patient recruitment which always focuses investor attention from a wider audience (Avion is funding at no cost to Immupharma). An RNS to that effect is going to be the only short term trigger on Lupuzor. There is also possible newsflow from any of the other four candidate drugs regarding development. The ONLY thing stopping this share taking off is continued concern over funding. The CEO said there was a cash runway to end 2024 but that is being questioned as is evident on this board. Any confirmation of funds, Royalty financing, licensing deal or ironically a significant increase in share price would immediately erase those concerns and it would take off here. The nature of the Lanstead deal means that any share increase over 2p has a chain reaction increase in finances but a decrease progressively reduces funds. You pays your money and takes your choice basically. DYOR. However, were one or all of the BoD to buy shares........

2 directly opposed views then.....how unusual. The constant, negative can't do brigade are that ones thar shackle British entrepreneurs and first movers. That's why so many companies are choosing to list in the US the land of can do optimism. The reversal here will take all by surprise.